Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis.
The authors have previously reported a model of ischemic bowel necrosis produced in the rat by synthetic platelet-activating factor (PAF) or a combination of PAF and bacterial endotoxin. Because rat platelets are refractory to PAF and thromboemboli were not found in the mesenteric or intestinal microvasculature, they suspected that secondary mediators were involved in the pathogenesis of bowel necrosis. They have found the following lipoxygenase products of arachidonic acid, especially leukotrienes (LT), probably played an important role in the pathogenesis of bowel necrosis, because diethylcarbamazine (an inhibitor for LTA synthesis) and FPL55712 (LT antagonist) ameliorated, and at times completely prevented, the lesions. NDGA (a nonspecific lipoxygenase inhibitor) was less effective, probably because of its additional effect on cyclooxygenase inhibition. Verapamil, a calcium channel blocker, ameliorated the disease. Thromboxane A2, a potent vasoconstrictor, was probably not responsible for the ischemia of the gastrointestinal tract. This is suggested by the ineffectiveness of OKY-046 in preventing bowel necrosis. Prostaglandin (PG) E1 infusion often prevented the bowel necrosis, which suggested beneficial effects of vasodilating PGs, probably released as a defense mechanisms. Indomethacin aggravated the disease, probably by inhibiting PG release and shifting the metabolic pathway toward the lipoxygenase pathway. Antihistamine and antiserotonin had no effect, which suggested that these mediators were not involved in the pathogenesis of bowel necrosis. Shock produced by PAF was probably not the only cause of bowel necrosis, because reversal of the hypotension did not always prevent the development of bowel necrosis. Hemoconcentration (increased vasopermeability) and leukopenia induced by PAF did not correlate with the development or severity of bowel necrosis.
Hsueh
W
W
Gonzalez-Crussi
F
F
Arroyave
J L
JL
D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D002396:Catechols / Q000494:pharmacology; D002867:Chromones / Q000494:pharmacology; D004049:Diethylcarbamazine / Q000494:pharmacology; D004195:Disease Models, Animal; D006400:Hematocrit; D007213:Indomethacin / Q000494:pharmacology; D007422:Intestines / Q000098:blood supply* / Q000473:pathology; D007511:Ischemia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors; D008297:Male; D009637:Masoprocol; D008689:Methacrylates / Q000494:pharmacology; D009336:Necrosis; D010972:Platelet Activating Factor; D051381:Rats; D011919:Rats, Inbred Strains; D012485:Salmonella typhi; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014700:Verapamil / Q000494:pharmacology
D002396:Catechols; D002867:Chromones; D008070:Lipopolysaccharides; D016859:Lipoxygenase Inhibitors; D008689:Methacrylates; D010972:Platelet Activating Factor; D009637:Masoprocol; C006312:FPL 55712; D014700:Verapamil; D013930:Thromboxane-A Synthase; D000527:Alprostadil; C034364:ozagrel; D004049:Diethylcarbamazine; D007213:Indomethacin